Download PDF
Semin Respir Crit Care Med 2003; 24(6): 717-726
DOI: 10.1055/s-2004-815667
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Aerosolized Antibiotics in Cystic Fibrosis

William P. Sexauer, Stanley B. Fiel
  • Division of Pulmonary/Critical Care Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
15 January 2004 (online)

    Permissions and Reprints

ABSTRACT

Inhaled antibiotics offer an attractive alternative to systemic administration in cystic fibrosis (CF) for several reasons. Antibiotics can be administered directly to the site of infection with little systemic absorption, thereby minimizing toxicity. Aerosolization will permit chronic administration of antipseudomonal antibiotics while avoiding the risks and inconvenience of intravenous access. Modern aerosolized drug delivery systems enable endobronchial delivery of very high antibiotic concentrations, resulting in clinical improvement even in patients with bacterial organisms that traditionally would have been considered resistant.

This article summarizes basic concepts of aerosol drug administration and reviews available data on the administration of a variety of drug classes for both suppressive therapy and acute exacerbations of cystic fibrosis, including toxicity and safety data. The aminoglycosides have been by far the most extensively studied class of antibiotics, culminating in U.S. Food and Drug Administration (FDA) approval of a specifically formulated tobramycin solution for inhalation. The available data on the development of antibiotic resistance and emergence of other organisms with long-term use of this agent are reviewed. Finally, a brief guideline for initiating and monitoring patients on antibiotic aerosols is provided for the clinician caring for CF patients.

KEYWORDS

Antibiotic - cystic fibrosis - tobramycin - Pseudomonas aeruginosa

REFERENCES

  • 1 Newman S P, Agnew J E, Pavia D, Clarke S W. Inhaled aerosols: lung deposition and clinical applications.  Clin Phys Physiol Meas . 1982;  3 1-20
    CrossrefPubMedGoogle Scholar
  • 2 Matthews L W, Doershuk C F. Inhalation therapy and postural drainage for the treatment of cystic fibrosis.  Bibliotheca Paediatrica . 1967;  86 297-314
    PubMedGoogle Scholar
  • 3 Clay M M, Pavia D, Newman S P, Clarke S W. Factors influencing the size distribution of aerosols from jet nebulisers.  Thorax . 1983;  38 755-759
    PubMedGoogle Scholar
  • 4 Newman S P, Pellow P GD, Clay M M, Clark S W. Evaluation of jet nebulisers for use with gentamicin solution.  Thorax . 1985;  40 671-676
    PubMedGoogle Scholar
  • 5 Newman S P, Woodrow G, Clarke S W. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern.  Thorax . 1988;  43 318-322
    PubMedGoogle Scholar
  • 6 Clay M M, Pavia D, Newman S P, Lennard-Jones T, Clarke S W. Assessment of jet nebulisers for lung aerosol therapy.  Lancet . 1983;  2 592-594
    PubMedGoogle Scholar
  • 7 Touw D J, Brimicombe R W, Hodson M E, Heijermann H GM, Bakker W. Inhalation of antibiotics in cystic fibrosis.  Eur Respir J . 1995;  8 1594-1604
    PubMedGoogle Scholar
  • 8 Eisenberg J, Pepe M, Williams-Warren J. et al . A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems.  Chest . 1997;  111 955-962
    PubMedGoogle Scholar
  • 9 Newman S P, Pavia D, Garland N, Clarke S W. Effects of various inhalation modes on the deposition of radioactive pressurised aerosols.  Eur J Respir Dis . 1982;  63 (suppl 119) S57-S65
    PubMedGoogle Scholar
  • 10 Mendelman P M, Smith A L, Levy J. et al . Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.  Am Rev Respir Dis . 1985;  132 761-765
    PubMedGoogle Scholar
  • 11 Levy J, Smith A L, Kenny M A. et al . Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in sputum.  J Infect Dis . 1983;  148 1069-1076
    PubMedGoogle Scholar
  • 12 Cooney G F, Lum B L, Tomaselli M. et al . Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis.  J Clin Pharmacol . 1994;  34 255-259
    PubMedGoogle Scholar
  • 13 Wall M A, Terry A B, Eisenberg J, McNamara M, Cohen R. Inhaled antibiotics in cystic fibrosis.  Lancet . 1983;  1 1325
    PubMedGoogle Scholar
  • 14 Steinkamp G, Tummler B, Gappa M. et al . Long-term tobramycin aerosol therapy in cystic fibrosis.  Pediatr Pulmonol . 1989;  6 91-98
    CrossrefPubMedGoogle Scholar
  • 15 Smith A L, Ramsey B W, Hedges D L. et al . Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis.  Pediatr Pulmonol . 1989;  7 265-271
    CrossrefPubMedGoogle Scholar
  • 16 Hodson M E, Penketh A RL, Batten I C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis.  Lancet . 1981;  2 1137-1139
    PubMedGoogle Scholar
  • 17 Carswell F, Ward C, Cook D A, Speller D CE. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the out-patient management of children with cystic fibrosis.  Br J Dis Chest . 1987;  81 356-360
    CrossrefPubMedGoogle Scholar
  • 18 Kun P, Landau L I, Phelan P D. Nebulized gentamicin in children and adolescents with cystic fibrosis.  Aust Paediatr J . 1984;  20 43-45
    PubMedGoogle Scholar
  • 19 MacLusky I, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa Pediatr Pulmonol .  1989;  7 42-48
    CrossrefPubMedGoogle Scholar
  • 20 Ramsey B W, Dorkin H L, Eisenberg J D, Gibson R I, Harwood I R, Kravitz R M. Efficacy of aerosolized tobramycin in patients with cystic fibrosis.  N Engl J Med . 1993;  328 1740-1746
    CrossrefPubMedGoogle Scholar
  • 21 Ramsey B W, Pepe M S, Quan J M. et al . Intermittent administration of inhaled tobramycin in patients with cystic fibrosis.  N Engl J Med . 1999;  340 23-30
    CrossrefPubMedGoogle Scholar
  • 22 Moss R B. Administration of aerosolized antibiotics in cystic fibrosis patients.  Chest . 2001;  120 (suppl 3) S107-S113
    CrossrefPubMedGoogle Scholar
  • 23 Moss R B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.  Chest . 2002;  121 55-63
    CrossrefPubMedGoogle Scholar
  • 24 Kosorok M R, Zeng L, West S HE. et al . Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.  Pediatr Pulmonol . 2001;  32 277-287
    CrossrefPubMedGoogle Scholar
  • 25 Emerson J, Rosenfeld M, McNamara S. et al . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.  Pediatr Pulmonol . 2002;  34 91-100
    CrossrefPubMedGoogle Scholar
  • 26 Wiesemann H G, Steinkamp G, Ratjen F. et al . Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.  Pediatr Pulmonol . 1998;  25 88-92
    CrossrefPubMedGoogle Scholar
  • 27 Ratjen F, Doring G, Nikolaizik W H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.  Lancet . 2001;  358 983-984
    CrossrefPubMedGoogle Scholar
  • 28 Gibson R L, Emerson J, McNamara S. et al . Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.  Am J Respir Crit Care Med . 2003;  167 841-849
    CrossrefPubMedGoogle Scholar
  • 29 Littlewood J M, Miller M G, Ghoneium A T, Ramsden C H. Nebulised colomycin for early Pseudomonas colonization in cystic fibrosis.  Lancet . 1985;  1 865
    PubMedGoogle Scholar
  • 30 Jensen T, Pedersen S S, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.  J Antimicrob Chemother . 1987;  19 831-838
    CrossrefPubMedGoogle Scholar
  • 31 Hodson M E, Gallagher C G, Govan J RW. et al . A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.  Eur Respir J. . 2002;  20 658-664
    CrossrefPubMedGoogle Scholar
  • 32 Valerius N H, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.  Lancet . 1991;  338 725-726
    CrossrefPubMedGoogle Scholar
  • 33 Vazquez C, Municio M, Corera M, Gaztelurrutia L, Sojo A, Vitoria J C. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.  Acta Paediatr . 1993;  82 308-309
    PubMedGoogle Scholar
  • 34 Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.  Pediatr Pulmonol . 1997;  23 330-335
    CrossrefPubMedGoogle Scholar
  • 35 Stead R J, Hodson M E, Batten J C. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa Br J Dis Chest .  1987;  81 272-279
    PubMedGoogle Scholar
  • 36 Huang N N, Hiller E J, Macri C M, Capitanio M, Cundy K R. Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation.  J Pediatr . 1971;  78 338-345
    PubMedGoogle Scholar
  • 37 Stephens D, Garey N, Isles A, Levison H, Gold R. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis.  Pediatr Infect Dis . 1983;  2 209-211
    PubMedGoogle Scholar
  • 38 Schaad U B, Wedgewood-Krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis.  J Pediatr . 1987;  111 599-605
    PubMedGoogle Scholar
  • 39 Alothman G A, Alsaadi M M, Ho B L. et al . Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin.  Chest . 2002;  122 930-934
    CrossrefPubMedGoogle Scholar
  • 40 Dodd M E, Abbott J, Maddison J, Moorcroft A J, Webb A K. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis.  Thorax . 1997;  52 656-658
    PubMedGoogle Scholar
  • 41 Hoffmann I M, Rubin B K, Iskandar S S. et al . Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.  Pediatr Pulmonol . 2002;  34 375-377
    CrossrefPubMedGoogle Scholar
  • 42 Smith A L, Fiel S B, Mayer-Hamblett H. et al . Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration lack of association in cystic fibrosis.  Chest . 2003;  123 1495-1502
    CrossrefPubMedGoogle Scholar
  • 43 Campbell P W, Saiman L. Consensus Conference: use of aerosolized antibiotics in patients with cystic fibrosis.  Chest . 1999;  116 775-788
    CrossrefPubMedGoogle Scholar
  • 44 LiPuma J J. Microbiological and immunologic considerations with aerosolized drug delivery.  Chest . 2001;  120 (suppl 3) S118-S123
    CrossrefPubMedGoogle Scholar
  • 45 Geller D E, Pitlick W H, Nardella P A, Tracewell W G, Ramsey B W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.  Chest . 2002;  122 219-226
    CrossrefPubMedGoogle Scholar
  • 46 Lin H C, Cheng H F, Wang C H. et al . Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis.  Am J Respir Crit Care Med . 1997;  155 2024-2029
    PubMedGoogle Scholar
  • 47 Barker A F, Couch L, Fiel S B. et al . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.  Am J Respir Crit Care Med . 2000;  162 481-485
    CrossrefPubMedGoogle Scholar
  • 48 Rusakow L S, Guarin M, Wegner C B. et al . Suspected respiratory tract infection in the tracheostomized child.  Chest . 1998;  113 1549-1554
    PubMedGoogle Scholar
  • 49 Stutman H R, Lieberman J M, Nussbaum E. et al . Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial.  J Pediatr . 2002;  140 299-305
    CrossrefPubMedGoogle Scholar
  • 50 Geller D E, Rosenfeld M, Waltz D A, Wilmott R W. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system.  Chest . 2003;  123 28-36
    CrossrefPubMedGoogle Scholar
  • 51 Crowther Labiris R N, Holbrook A M, Chrystyn H. et al . Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis.  Am J Respir Crit Care Med . 1999;  160 1711-1716
    PubMedGoogle Scholar